Clinical trials: Cancer Progression
Parkinson's, Parkinson Disease
Longitudinal Investigation of I2BS in PD
In this study, the researchers aim to find a biomarker of PD. Using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI).
- Conditions
- Parkinson's, Parkinson Disease, Parkinson's Disease, Neurodegenerative Diseases
- Trial name
- FOX_2 (NCT05516719)
- Testing
- Positron Emission Tomography (PET) scan using BU99008 tracer, FP-CIT Single-photon Emission Computed Tomography (SPECT) scan, Magnetic Resonance Imaging (MRI) Scan
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Exeter
Coronary Artery Disease Premature, Angina, Stable
Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease
The new global guidelines from the World Health Organization on air quality provide evidence of the damage that air pollution inflicts on human health at even lower concentrations than previously thought.
- Conditions
- Coronary Artery Disease Premature, Angina, Stable, Acute Coronary Syndrome, MINOCA
- Trial name
- AIRHEART (NCT06464042)
- Where
- Spain
- Volunteers
- 4,272 people
- Sponsor
- pablo Juan-Salvadores
Adolescence Idiopathic Scoliosis
Machine Learning Prediction of Disease Progression in Adolescent Idiopathic Scoliosis
Background and Problem Overview Adolescent Idiopathic Scoliosis (AIS) is a progressive musculoskeletal disorder characterized by a three-dimensional deformation of the spine occurring during adolescence.
- Trial name
- NCT07556042
- Testing
- Core Stabilization Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University
Covid19
Impact of Colchicine and Low-dose Naltrexone on COVID-19
The purpose of this study is to explore the impact of two medications-colchicine and low-dose naltrexone (LDN)-relative to standard of care (SOC) on COVID-19 disease progression to severe/critical illness and/or intubation in…
- Trial name
- COLTREXONE (NCT04756128)
- Testing
- Colchicine 0.6 mg, Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- HealthPartners Institute
Parkinson Disease
Neuro-immune Interactome in Parkinson's Disease
This study will be observational and have a prospective case-control longitudinal design. Eligible subjects with idiopathic REM behavior disorder (RBD), Parkinson's disease with RBD, and healthy controls will be recruited.
- Trial name
- NCT07026929
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Yale University
Locally Advanced Non-Small Cell Lung Cancer, NSCLC
Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy
A phase II study of combination therapy of carboplatin -gemcitabine plus bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior…
- Trial name
- NCT00702975
- Testing
- Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Radboud University Medical Center
Inflammatory Joint Diseases, Rheumatoid Arthritis (RA)
Oxidative Stress in Autoimmune Rheumatic Diseases
Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus…
- Conditions
- Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS)
- Trial name
- REDOX-ARD (NCT07536529)
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- University of Thessaly
Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2
Vitamin D Supplement in patients with CKD stage 1 and 2 may change osteoprotegin expression so as to produce beneficial effects of cardiovascular、bone metabolism and CKD progression.
- Trial name
- NCT01561222
- Testing
- Calcitriol
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Taixing People's Hospital
Stroke, Acute, Educational Problems
Off-script Diagnosis & Differential Diagnosis (D&D) Training and Residents' Stroke Knowledge
This study is a single-center, randomized, open-label, controlled, endpoint-blinded study to assess the effect of off-script diagnosis \& differential diagnosis (D\&D) training in improving the residents' knowledge of acute…
- Conditions
- Stroke, Acute, Educational Problems, Clinical Course
- Trial name
- CAST-AIS (NCT06941753)
- Testing
- Off-script diagnosis & differential diagnosis (D&D) training
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
ESCC
Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study
This prospective, single-arm phase II study will evaluate the efficacy and safety of lymphatic-drainage-sparing short-course radiotherapy combined with camrelizumab and nab-paclitaxel/carboplatin as neoadjuvant treatment for…
- Trial name
- NeoSCRTIC-01 (NCT07808853)
- Testing
- Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Bladder Cancer, Bladder Cancer Recurrence
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
Bladder cancer is a highly heterogeneous malignancy characterized by frequent genetic alterations that are closely associated with disease progression, recurrence risk, and treatment response.
- Conditions
- Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer, Progression of Bladder Cancer
- Trial name
- NCT07424560
- Testing
- Multiplex Mutation Detection System for Bladder Cancer (Nucleic Acid Mass Spectrometry)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zhilong Dong
Prostate Cancer
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate…
- Trial name
- NCT00670046
- Testing
- valproic acid, standard of care follow-up
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2-positive Breast Cancer, Recurrent Breast Cancer
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
The purpose of this study is to see whether a combination of two different drugs - trastuzumab-MCC-DM1 (T-DM1) and BYL719 is safe, and if it might be effective in treating metastatic breast cancer.
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT02038010
- Testing
- PI3K inhibitor BYL719, ado-trastuzumab emtansine, pharmacological study
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Breast Cancer
Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
This study evaluates whether there are pre-treatment factors such as patient characteristics, specific breast cancer type, specific treatments, toxicities, or adverse events during treatment that may impact the quality of life…
- Trial name
- NCT05926024
- Testing
- Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes
- Where
- United States
- Volunteers
- 253 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Patients who have histologically confirmed metastatic or unresectable (not amenable to curative therapy) breast cancer may be screened for eligibility.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
- Trial name
- NCT04762979
- Testing
- Alpelisib, Fulvestrant, Aromatase inhibitor
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Marina N Sharifi
Diabetes Mellitus, Type II
Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
This is a prospective, randomized, active control, two-arm parallel, double-blind, monocenter phase IV clinical trial. The trial compares empagliflozin to glimepiride in patients with type 2 diabetes mellitus in addition to…
- Trial name
- NCT02985242
- Testing
- Empagliflozin, Glimepiride
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Hannover Medical School
Uterine Bleeding, Uterine Cancer
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression
The investigators will obtain urine hormone results and validated menstrual bleeding score from people experiencing abnormal uterine bleeding. The investigators will evaluate satisfaction and ease of use of Mira monitor.
- Conditions
- Uterine Bleeding, Uterine Cancer, Uterine Neoplasms, Endometrial Cancer
- Trial name
- MIRA (NCT07581288)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of British Columbia
Hypertension
Progression Evaluation and Genetic Determinants of Hypertension in Chinese - A Follow-up Study of Taiwan SAPPHIRe
The purpose of this study is to determine the progression evaluation and genetic determinations of hypertension in Chinese
- Trial name
- NCT00260910
- Where
- Taiwan
- Volunteers
- 1,246 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Parkinson Disease, Cognitive Dysfunction
Predictors of Parkinson's Disease Progression
it is a prospective longitudinal observational study, aiming to to identify clinical, and biochemical baseline predictors of motor and non-motor PD progression in sample of Egyptian patients.
- Conditions
- Parkinson Disease, Cognitive Dysfunction, Biomarkers
- Trial name
- PDPROG-EGY (NCT04062279)
- Testing
- serum alpha synuclein autoantibodies, motor and non motor scales
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Non-Small-Cell Lung Carcinoma
Molecular Imaging With Erlotinib and Bevacizumab
The patients will be treated with erlotinib and bevacizumab for a six-week period. Imaging procedures will be performed at baseline, after one week of therapy and after the six weeks of treatment.
- Trial name
- MIMEB (NCT01047059)
- Testing
- Erlotinib, Bevacizumab, Fluoro-D-glucose, Fluoro-L-thymidine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Cologne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.